Try our beta test site
24 studies found for:    stx209
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting MEG Study of STX209
Condition: Autism Disorder
Interventions: Drug: STX209;   Drug: placebo
2 Terminated Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: STX209 (arbaclofen)
3 Terminated An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: arbaclofen
4 Completed
Has Results
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: STX209;   Drug: Placebo
5 Completed
Has Results
Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: Arbaclofen
6 Terminated An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: Arbaclofen
7 Completed Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: arbaclofen;   Drug: placebo
8 Completed Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: Arbaclofen
9 Completed Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: arbaclofen;   Drug: Placebo
10 Completed One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
Conditions: Multiple Sclerosis;   Spasticity
Intervention: Drug: arbaclofen
11 Completed A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
Condition: Alcohol Use Disorder
Interventions: Drug: Arbaclofen Placarbil;   Drug: Placebo
12 Recruiting A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers
Condition: Healthy Volunteers
Interventions: Drug: Arbaclofen Placarbil SR;   Drug: Arbaclofen Placarbil MR Prototype A;   Drug: Arbaclofen Placarbil MR Prototype B;   Drug: Arbaclofen Placarbil IR
13 Recruiting To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS
Conditions: Multiple Sclerosis;   Sperm
Interventions: Drug: arbaclofen ER Tablets;   Drug: Placebo for arbaclofen ER tablets
14 Completed Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
Conditions: Spasticity;   Multiple Sclerosis
Interventions: Drug: arbaclofen;   Drug: baclofen;   Drug: Placebo
15 Completed Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001
Condition: Fragile X Syndrome
Intervention: Drug: STX209
16 Completed Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Arbaclofen placarbil 15 mg BID;   Drug: Placebo;   Drug: Arbaclofen placarbil 30 mg BID;   Drug: Arbaclofen placarbil 45 mg BID
17 Terminated An Open Label Extension Study in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: arbaclofen
18 Completed Biomarker and DNA Collection in Subjects Participating in Protocol 22003
Condition: Fragile X Syndrome
Intervention: Drug: STX209
19 Completed A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
Condition: Gastroesophageal Reflux Disease
Interventions: Drug: arbaclofen placarbil-Cohort 1;   Drug: Placebo-Cohort 5;   Drug: arbaclofen placarbil-Cohort 2;   Drug: arbaclofen placarbil-Cohort 3;   Drug: arbaclofen placarbil-Cohort 4;   Drug: PPI
20 Completed A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms
Condition: Back Pain
Interventions: Drug: Arbaclofen placarbil, 20 mg;   Drug: Placebo;   Drug: Arbaclofen placarbil, 30 mg;   Drug: Arbaclofen placarbil, 40 mg

   Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.